Molina-Holgado E, Dewar K M, Descarries L, Reader T A
Département de Physiologie, Faculté de Médecine, Université de Montréal, Quebec, Canada.
J Pharmacol Exp Ther. 1994 Aug;270(2):713-21.
3,4-Dihydroxyphenylalanine (L-DOPA), 5-hydroxy-l-tryptophan (5-HTP), dopamine (DA), 5-hydroxytryptamine (5-HT) and their metabolites were measured in the rostral neostriatum of adult rats neonatally lesioned with 6-hydroxydopamine (6-OHDA) after treatment with NSD-1015 (aromatic L-amino acid decarboxylase inhibitor), pargyline (monoamine oxidase inhibitor) or probenecid (blocker of acidic metabolite efflux). Binding experiments with DA and 5-HT transporter ligands allowed us to relate observed changes to the number of DA and 5-HT terminals. One and 3 months after the lesions were made, DA, 3,4-dihydroxyphenylacetic acid (DOPAC)- and homovanillic acid (HVA)-content as well as [3H]N-[1-(2-benzo(b)-thiophenyl)cyclohexyl]piperidine ([3H]BTCP) binding were lowered to 1% to 2% of control values, reflecting a permanent DA denervation. After 1 month, 5-HT content was increased by 96% and 5-hydroxyindole-3-acetic acid (5-HIAA) was increased by 50% in the presence of control levels of [3H]citalopram binding, suggesting that there was an increased amount of 5-HT per neostriatal 5-HT terminal. At 3 months, 5-HT content had increased by 205%, 5-HIAA remained increased by 50% and [3H]citalopram binding had reached 170% of control values, indicating a persistent increase in 5-HT content within an excessive number of 5-HT terminals (hyperinnervation). At both survival times, neostriatal L-DOPA accumulation after NSD-1015 was low, but ratios of L-DOPA to DA and of L-DOPA to [3H]BTCP were greatly elevated. 5-HTP accumulation was increased, but ratios of 5-HTP to 5-HT were lower than control, despite unchanged ratios of 5-HTP to [3H]citalopram.(ABSTRACT TRUNCATED AT 250 WORDS)
在用6-羟基多巴胺(6-OHDA)对新生大鼠进行损伤后,分别用NSD-1015(芳香族L-氨基酸脱羧酶抑制剂)、帕吉林(单胺氧化酶抑制剂)或丙磺舒(酸性代谢物外排阻滞剂)处理成年大鼠,然后测定其吻侧新纹状体中3,4-二羟基苯丙氨酸(L-多巴)、5-羟基-L-色氨酸(5-HTP)、多巴胺(DA)、5-羟色胺(5-HT)及其代谢物的含量。用DA和5-HT转运体配体进行的结合实验使我们能够将观察到的变化与DA和5-HT终末数量联系起来。损伤后1个月和3个月,DA、3,4-二羟基苯乙酸(DOPAC)和高香草酸(HVA)含量以及[3H]N-[1-(2-苯并(b)噻吩基)环己基]哌啶([3H]BTCP)结合量降至对照值的1%至2%,这反映了永久性的DA去神经支配。1个月后,在[3H]西酞普兰结合水平处于对照水平时,5-HT含量增加了96%,5-羟基吲哚-3-乙酸(5-HIAA)增加了50%,这表明每个新纹状体5-HT终末的5-HT量有所增加。3个月时,5-HT含量增加了205%,5-HIAA仍增加了50%,[3H]西酞普兰结合量达到对照值的170%,这表明在过量的5-HT终末(超神经支配)内5-HT含量持续增加。在两个存活时间点,NSD-1015处理后新纹状体L-多巴的积累量都很低,但L-多巴与DA的比值以及L-多巴与[3H]BTCP的比值大幅升高。5-HTP的积累量增加了,但5-HTP与5-HT的比值低于对照,尽管5-HTP与[3H]西酞普兰的比值没有变化。(摘要截短至250字)